ARCA biopharma, Inc., a precision medicine-focused biopharmaceutical company, has announced a merger agreement with Oruka Therapeutics, Inc. The merger is intended to qualify for federal income tax purposes as a tax-free reorganization and is highly dependent on the success of the companies' future operations.